



Aligning global value-based decision making

THE CIRS 2020 AGENDA

CONSENSUS • TRUST • ACCESS



MISSION

To maintain a leadership role in identifying and applying scientific principles for the purpose of advancing regulatory and health technology assessment (HTA) policies and processes in developing and facilitating access to medicinal products

KEY ACTIVITIES

International Workshops: Meetings for members are convened at which invited participant interactions are optimised to facilitate networking, constructive discussion, recommendations and actions.

CIRS Research Projects: Specialised research and surveys are carried out among leading pharmaceutical companies and regulatory and HTA agencies with expert analyses and interpretation of the findings.

Identification of and Advocacy for International Best Practices: Using findings from our Workshops and research projects CIRS interacts with companies, regulators, HTA agencies and other international organisations to promulgate efficiencies in global medicine development.

Publications and Presentations: Reports are prepared from Workshops and projects. Dissemination of findings and recommendations through the R&D Briefing series, conference presentations, papers in peer-reviewed journals and the CIRS website are key aspects of the CIRS educational communication mission.

CIRS: VALUE, IMPACT, RETURN


For over 25 years, the Centre for Innovation in Regulatory Science (CIRS) has provided a neutral forum for the evolution of the concepts, methodologies and policies that improve the effectiveness, efficiency and decision making of stakeholders in the development of and access to safe and effective medicines.

How does CIRS provide value?

- Facilitating interaction among stakeholders
- Evolving best practices
- Offering decision-making tools
- Providing data and analyses to inform policy decisions
- Demonstrating the relevant application of metrics
- Strengthening agency capacity
- Aligning regulatory and HTA needs
- Recording and communicating situational analyses

CIRS Workshops provide exceptional learning and networking opportunities where participants can interact with peers in an atmosphere of informed and productive discussion to produce recommendations to move important topics forward in the development, regulation and reimbursement of medicines.

CIRS Workshops: impact and return on investment



2020 WORKSHOPS

15-16 September (virtual meeting)


Effectiveness of the Regulatory Approval Process – Moving from Measuring Performance to Operational Excellence

OBJECTIVES

- Discuss what is required beyond measuring just time to understand a regulatory authority's performance and how this can be utilised by agencies to improve their effectiveness
- Identify comparative measures of effectiveness that could allow for cross agency learning
- Make recommendations on a common set of key indicators across authorities that could be used as a measure of effectiveness

Key discussion points:

- Having an effective regulatory approval process: why is it important and what does this mean to stakeholders?
- Quality of Dossier submission - how does this influence the effectiveness of the review and what can be done to ensure quality?



8-9 December (virtual meeting)

Reimagining medicine regulatory models: implementing fit for purpose activities for sustainable patient access?

A memorial workshop dedicated to Prof Sir Alasdair Breckenridge

OBJECTIVES

- Discuss current regulatory models and whether the regulatory paradigm for development and review need to evolve to meet current and evolving needs?
- Identify opportunities and challenges to re-imagine the regulatory assessment process:
 - Potential areas for change that have been exposed by the pandemic
 - The traditional areas of activity the pandemic has exposed and that can be adapted flexibly; which of these can form the basis of a sustainable model(s) across all products and therapy areas post-pandemic
 - Activities that have increased (i.e. collaborations, scientific advice) or have been accelerated (i.e. clinical trial models) by the pandemic
- Make recommendations on activities that should be considered to evolve a sustainable, fit-for-purpose model(s) for the development, review and access of new medicines.

Early March 2021, Runnymede Hotel, Surrey, UK

Regulatory and HTA Interactions in the Development Space – Is this Enabling Better Evidence Generation, Improved Probability of Success and Patient Access?


OBJECTIVES

- Discuss the current and future interactions and collaborations landscape within and across the different stakeholders HTAs, regulators, payers.
- Identify through case studies the key areas and types of interactions and collaborations between stakeholders which are effective models, as well as the challenges and opportunities
- Understand the value-add these interactions and collaborations bring to enabling improved decision making by the different stakeholders as well as the nature of divergence and limitations
- Make recommendation on what can be learnt across jurisdictions from the current initiatives so as to inform the future evolution of stakeholder interactions and collaborations and how they can enable better evidence generation as well as improved probability of success and patient access



THE CIRS REGULATORY AND ACCESS PROGRAMME

Following advice from the Scientific Advisory Board (SAC), CIRS activities in the regulatory and access arenas were fully aligned in 2019. Because of CIRS' special ability to coordinate the input and activities of multiple stakeholders from a global perspective, the "Regulatory and Access Programme" addresses our activities in this holistic manner. The HTA Steering Committee advises CIRS on HTA-specific activities related to the Programme.



DRIVING THEMES

METRICS

Managing uncertainty and improving predictability

QUALITY OF PROCESS

Improving development and regulatory processes and ultimately, the quality of decision making

ALIGNMENT

Promoting convergence within and across organisations and stakeholders

THE 2020 PROGRAMME OF WORK: EVOLUTION OF THE DELIVERABLES


2015-2017		2018-2020
GLOBAL DEVELOPMENT PROGRAMME TRACK	HTA TRACK	COMBINED "REGULATORY AND ACCESS PROGRAMME"
2 paid registrations per Workshop (3 Workshops)	1 paid registration per Workshop (3 Workshops)	Two paid registrations per Workshop (3 Workshops per year)
Global Development (regulatory focused) Technical Forum (annual)		Regulatory-focussed Technical Forum (annual) registration fee included (accommodation not included)
Regulatory advocacy with ICH+ countries	European, Canadian and US HTA advocacy	Aligned regulatory and access advocacy with ICH+ countries
	HTA focussed Technical Forum (annual)	HTA/HEOR-focussed Technical Forum (annual) - registration fee included (accommodation not included)
Targeted international regulatory advocacy	Advocacy with access agencies in the global environment	Aligned global international advocacy across regulatory and access agencies
Support for the Annual Regulator's Forum		Support for the Annual Regulator's Forum; ad hoc Agency Discussion Meetings; new periodic HTA agency webinars
	Semi-annual HTA teleconferences	Semi-annual teleconferences (2 regulatory focus and 2 HTA/HEOR focus)
Focus Study participation	Focus Study participation	Focus Study participation across regulatory and access topics
Regulatory agency performance metrics benchmarking		Regulatory agency performance metrics benchmarking; HTADock integrated regulatory and HTA database outcomes analyses
Key regulatory projects: benefit-risk, International Summary Approach to Benefit Risk Evaluation (iSABRE), PhD student support	Key HTA projects: Factors influencing HTA recommendations in Europe; Exploring Approaches to HEOR/HTA decision making; Commonality in evidentiary requirement across regulatory and HTA stakeholders	Key aligned projects <ul style="list-style-type: none"> • Regulatory: iSABRE • Quality Scorecards/Decision Making activities; Facilitated regulatory and access pathways; Commonality in evidentiary requirement across regulatory and HTA stakeholders • PhD student support-regulatory and HTA thesis themes

CIRS ACTIVITIES 2018-2020

RESEARCH THEMES

The Centre for Innovation in Regulatory Science addresses a wide range of topics related to the development, regulatory review and reimbursement of medicines. The driving themes for the rolling three-year programme 2018-2020 have been as follows:

- Enabling Innovation and Upstream Partnering to Enhance Downstream Innovation
- Pragmatic Approaches to Transparent Decisions: Reliance, Recognition, Reciprocity and Regionalisation
- Patient Engagement and "Centricity"
- Disruptive Technologies: The Impact of Digital and Other Technologies on Development, Regulation and Value



ACHIEVEMENTS FOR 2018-2019

CIRS has been disseminating its research outputs and tools through a number of channels:

- **9 Research and Development Briefings** to disseminate high level findings from original research and to address important policy changes, for example: regulatory review process approvals by global regulatory agencies, the review of HTA outcomes as well as the sequence of regulatory and HTA processes
- **12 Publications in Peer-Reviewed Journals** by CIRS staff as well as a result of collaborations with PhD students whose studies are jointly supervised by CIRS and Utrecht University or University of Hertfordshire
- **6 International Workshops** organised by CIRS with participants from 50+ organisations from across academia, regulatory and HTA agencies as well as patient groups, with actionable recommendations developed from each meeting
- **18 Poster and Podium Presentation** at major regulatory and HTA Conferences and Fora
- **35+ visits with senior staff from regulatory authorities and HTA/Payer bodies** in Europe, USA, Africa, Asia, Latin America and the Middle East in order to identify current practice and to promote the use of CIRS tools and international best practice

CIRS publications, briefings and workshop reports can be viewed at www.cirsci.org

WHAT OUR STAKEHOLDERS SAY

"CIRS Workshops provide an excellent opportunity to meet top management from EMA and FDA. Good open discussion between stakeholders that I have not experienced before." Pharmaceutical company


"CIRS Research and Development Briefings provide very useful information as we have to account for our timelines to our principals in the face of shortages of critical medicines. The snippets of ideas on how other resource limited agencies managed to work smarter will help us use our meagre resources strategically and efficiently." Regulatory agency

"The overall quality of discussions at CIRS Workshops is excellent, the engagement with and by the HTA/payer community is impressive and sets a nice course forward" HTA agency


ONGOING PROJECTS AND ACTIVITIES FOR 2020

As part of our aligned Regulatory and Access Programme, CIRS will continue with the following research activities in 2020:

REGULATORY RESEARCH PROGRAMMES



HTA RESEARCH PROGRAMMES



SPECIAL PROJECTS

CIRS' status as a trusted resource as well as its extensive experience has been recognised by organisations through the commissioning of Special Projects. Examples of collaborating organisations include the ICH, WHO, Gates Foundation, PhRMA and Centres of Excellence as well as member companies and agencies. CIRS welcomes suggestions and ideas for future projects.


PLANNING BEYOND 2020

A rolling, three-year programme of discussion topics will be maintained in consultation with the CIRS SAC and HTA Steering Committee as well as member companies and agencies. The aim will be to allow rapidly developing issues to be included on the 2021-2023 research agenda in addition to the major ongoing CIRS research projects. Proposed agenda topics from the SAC are outlined below, but we always welcome suggestions as long as they are within the scope of our mission and objectives.

Bringing the patient viewpoint into the decision-making process
 Measuring the impact of patient involvement in review and reimbursement

Acceptance of a collaborative/work sharing environment
 Building trust across regions and between agencies

Convergence of technologies and its impact on regulation For example complex combination therapies, digital health, historical controls



Improving predictability of regulatory and HTA outcomes
 Alignment of patient, regulatory and HTA priorities to expedite access to medicines

Regionalisation is key
 The importance of reliance models, work sharing approaches and regionalisation to support availability of new medicines globally

Change culture to accept new types of endpoints
 Translating real-world evidence/data into regulatory-grade evidence

MEMBER COMPANIES AND PARTICIPATING AUTHORITIES

Member Companies

USA	Europe	Japan
AbbVie	AstraZeneca	Astellas
Amgen	Bayer	Eisai
Biogen	GlaxoSmithKline	Takeda
CSL Behring	Ipsen	
Eli Lilly and Co.	Leo	
Johnson & Johnson	Lundbeck	
Merck & Co	Novartis	
Pfizer	Roche	
	Sanofi	
	UCB	

HTA and Coverage Bodies

Country	Organisation
Australia	PBAC
Belgium	INAMI; KCE
Brazil	CONITEC
Canada	CADTH; DSEN, Canadian Institutes of Health Research, INESSS, Alberta Health Services
Croatia	AAZ
Denmark	Danish Health and Medicines Authority
England, Wales	NICE
Europe	EUnetHTA
Finland	THL
France	HAS
Germany	G-BA, AOK-Bundesverband
Italy	AIFA
Lithuania	VASPV
Norway	NOKC
Poland	AHTAPol
Portugal	INFARMED
Scotland	Scottish Medicines Consortium
Singapore	ACE
Spain	CAHIAQ, Osteba
Sweden	TLV
Switzerland	BAG
The Netherlands	ZIN
United States	UnitedHealth Group; TEC, Blue Cross/Blue Shield Association; Kaiser Permanente Institute for Health Policy; AHRQ; OPTUM

Participating Regulatory Authorities

Asia - Country	Authority
Australia	TGA
China	NMPA
Chinese Taipei	TFDA; CDE
Indonesia	NAFDC
Japan	MHLW, PMDA
Malaysia	NPRA
Philippines	PFDA
Singapore	HSA
South Korea	MFDS
Thailand	Thai FDA
Vietnam	DAV
Regional initiatives	APEC

Participating Regulatory Authorities

Americas - Country	Authority
Argentina	ANMAT
Brazil	ANVISA
Canada	Health Canada
Chile	ANAMED
Colombia	INVIMA
Cuba	CECMED
Haiti	DPM/MT-MSPP
Mexico	COFEPRIS
Peru	DIGEMID
United States	FDA
Regional initiatives	CARICOM-CRS/PAHO

EME - Country	Authority
Denmark	Danish Health and Medicines Authority
EU	EMA
Ireland	HPRA
Israel	MoH
Jordan	JFDA
Kuwait	KDFC
Oman	MoH
Qatar	SCH
Saudi Arabia	SFDA
Sweden	MPA
Switzerland	Swissmedic
The Netherlands	MEB
Turkey	TITCK
United Arab Emirates	MoH
United Kingdom	MHRA
Regional initiatives	GHC

Africa - Country	Authority
Botswana	BoMRA
Burkina Faso	MoH
Ethiopia	EFDA
Gambia	MCA
Ghana	FDAG
Kenya	PPB
Mozambique	MoH
Namibia	NMRC
Nigeria	NAFDAC
Senegal	MoHP
South Africa	SAHPRA
Tanzania	TMMDA
Zambia	ZAMRA
Zimbabwe	MCAZ
Regional initiatives	AMRH-EAC, Zazibona/SADC, WAHO

Scientific Advisory Council

Chair: Adjunct Prof John Skerritt, Deputy Secretary for Health Products Regulation, Department of Health, Canberra, Australia
Vice-Chair: Prof Hans-Georg Eichler, Senior Medical Officer, EMA

Dr Claus Bolte, Head of Sector Marketing Authorisation, Swissmedic

Dr Harald Enzmann, Chair, CHMP/EMA

Dr Ian Hudson, Senior Advisor, Integrated Development, Global Health, Bill and Melinda Gates Foundation, UK

Prof John Lim, Professor of Practice, Executive Director of CoRE, Duke-NUS Medical School and Policy Lead, SingHealth Duke-NUS Global Health Institute

Dr Theresa Mullin, Director, Office of Strategic Programs, US FDA, CDER

Dr Brian O'Rourke, Former CEO and President, CADTH, Canada

Dr Junko Sato, Office Director, Office of International Program, Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Dr Xie Songmei, Deputy Director of Clinical Department Center for Drug Evaluation, NMPA, China

Dr John Patrick Stewart, Director General, Therapeutic Products Directorate, Health Canada

Deborah Autor, Global Head of Regulatory Excellence, AstraZeneca, USA

Dr Fabio Bisordi, Global Head International Regulatory Policy, F.Hoffmann-La Roche Ltd

Dr Tim Garnett, CMO, SVP, Eli Lilly
Adrian Griffin, Vice President for HTA Policy, Johnson & Johnson

Dr Peter Honig, Senior Vice President and Head of Worldwide Safety and Regulatory, Pfizer

Mark Hope, Senior Vice President, Global Regulatory Head, UCB

Dr David Jefferys, SVP, Head of Global Regulatory, Eisai Europe Ltd

Dr Sabine Luik, Chief Regulatory Officer, SVP, Global Regulatory Affairs and Quality Assurance, GlaxoSmithKline

Dr Roopal Thakkar, Vice President, Global Regulatory Affairs, Abbvie

Dr Max Wegner, Head Regulatory Affairs PH & CH, Bayer AG

Dr Jamie Munro, Executive Director, CIRS

Dr Neil McAuslane, Director, CIRS

Dr Lawrence Liberti, Head, Regulatory Collaborations, CIRS

Prof Stuart Walker, Founder, CIRS

Specialist Advisors to the Executive Director

Dr Thomas Lönngren, Former Executive Director, EMA

Dr Murray Lumpkin, Deputy Director, Integrated Development, and Lead for Global Regulatory Systems Initiatives, Bill and Melinda Gates Foundation

Prof Mamoru Narukawa, Associate Professor Pharmaceutical Medicine, Kitasato University Graduate School of Pharmaceutical Sciences, Tokyo, Japan

Dr Tomas Salmonson, Former Chair, CHMP/EMA

Dr Joseph Scheeren, President, CEO, Critical Path Institute

HTA Steering committee

Chair: Dr Brian O'Rourke, Former CEO and President, CADTH, Canada

Vice-Chairman: Prof Adrian Towse, Director Emeritus and Senior Research Fellow, OHE

Dr Nick Crabb, Programme Director, Scientific Affairs, NICE

Prof Hans-Georg Eichler, Senior Medical Officer, EMA

Dr Wim Goettsch, Associate Professor HTA, Utrecht University; Special Advisor HTA, ZIN

Evert Jan van Lente, Director EU-Affairs, AOK-Bundesverband

Niklas Hedberg, Chief Pharmacist, TLV

Andrew Mitchell, Strategic Adviser, DoHA

Adrian Griffin, Vice President for HTA Policy, Johnson & Johnson

Dr Michael Happich, Director, BioMed HTA, Eli Lilly and Co

Dr Adam Heathfield, Senior Director, Patient and Health Impact Innovation Centre, Pfizer

Dr Maria Kubin, Head, Integrated Evidence Planning for Cardiovascular TA, Bayer

Dr Vanessa Elisabeth Schaub, Global Access Senior Health Systems Strategy Leader HTA & Reimbursement, Roche

Dr Sean Tunis, Principal, Rubix Health and Senior Advisor, FDA

Prof Finn Børlum Kristensen, Former EUnetHTA Executive Committee Chairman and EUnetHTA Secretariat Director, Faculty of Health Sciences, University of Southern Denmark

Dr Lawrence Liberti, Head, Regulatory Collaborations, CIRS

Dr Neil McAuslane, Director, CIRS

Dr Jamie Munro, Executive Director, CIRS

Tina Wang, Manager, HTA Programme, CIRS

TOOLS TO FACILITATE DECISION MAKING

CIRS develops tools to facilitate decision making within companies, regulatory and HTA agencies, with the overarching aim to increase transparency of processes, support quality decision making and provide global advocacy in support of regulatory and HTA strengthening. CIRS tools are used in special projects with individual companies and agencies but are also available for an organisation's own use.

Navigating pathways

The **CIRS Regulatory and Reimbursement Atlas™** maps interactions between regulators, HTA agencies and payers across 56 jurisdictions, helping organisations to navigate the increasingly complicated regulatory and reimbursement landscape.


Find out more by visiting:
www.cirs-atlas.org
(Free for CIRS members)



Assessing quality of decision making

CIRS has developed **10 Quality Decision-Making Practices** to help organisations monitor decision-making processes, improve awareness about best practice and reduce uncertainty.

Implementation of these practices is assessed using the **Quality of Decision-Making Orientation Scheme (QoDoS®)**.



Regulatory scorecards

The **CIRS Quality Scorecard** is an internationally accepted scorecard system for monitoring the quality of regulatory submission (completed by agencies) and their review (completed by companies).



Benefit risk decisions

UMBRA is a universal framework bringing together methodologies for benefit risk.

It includes two tools:

- **CIRS-BRAT**, for visualising and assessing benefit risk. Download at: www.cirs-brat.org
- **iSABRE**, which documents benefit risk through a summary template.



BENEFITS OF MEMBERSHIP



Membership to the Regulatory and Access Programme is open to all pharmaceutical companies, in particular those engaged in research and development of new active substances, prescription medicines, devices and biologics with a view to global product development, regulatory affairs and market access.

The benefits enjoyed by members of CIRS include:

- Be part of the small interactive CIRS Workshops, which provide exceptional learning and networking opportunities where you can interact with peers from industry, regulatory authorities, HTA agencies and academia in an atmosphere of informed and productive discussion
- Full registration and accommodation (excluding travel) for two participants at each Workshop
- The opportunity to meet and network with senior regulatory personnel from government agencies, international pharmaceutical companies and academia
- The ability to contribute to the direction of the programme of work for CIRS and put forward subjects for discussion and debate at future Workshops as well as topics for surveys and studies
- The opportunity to be nominated for participation in the Advisory Management Committee or the Scientific Advisory Council, Steering Committees and Taskforces
- Exclusive, priority access to
 - Information derived from studies and surveys to which your organisation has contributed
 - Reports and slide presentations from CIRS Workshops
- Early access to
 - Reports and supportive documents from all Workshops and projects, projects highlighting regulatory and HTA developments, issues and attitudes as a unique information resource
 - Archives of all CIRS publications including survey and Workshop reports and R&D Briefings

The fee for the 2020 Regulatory and Access Programme entitles member organisations to all of the benefits of membership described in this brochure; this includes the full registration and accommodation (excluding travel) for two participants at each Workshop and registration for one person to each of the annual Forums. Additional participants may attend Workshops (space permitting) and will be assessed a registration fee (£950 per person per Workshop plus VAT where applicable), to cover direct participation costs (conference rate, meals and accommodations, administration and overhead; travel excluded).

The Centre for Innovation in Regulatory Science (CIRS) is a neutral, independently managed UK-based subsidiary company, forming part of the Clarivate Analytics group. CIRS' mission is to maintain a leadership role in identifying and applying scientific principles for the purpose of advancing regulatory and HTA policies and processes. CIRS provides an international forum for industry, regulators, HTA and other healthcare stakeholders to meet, debate and develop regulatory and reimbursement policy through the innovative application of regulatory science and to facilitate access to medical products. This is CIRS' purpose. CIRS is operated solely for promotion of its purpose. The organisation has its own dedicated management and advisory boards, and its funding is derived from membership dues, related activities, special projects and grants.

Centre for Innovation in Regulatory Science (CIRS)
Friars House, 160 Blackfriars Road, London SE1 8EZ, United Kingdom

Email: cirs@cirsci.org

Website: www.cirsci.org

www.linkedin.com/company/centre-for-innovation-in-regulatory-science-ltd/

Dr Jamie Munro, Executive Director

jamie.munro@cirsci.org

Dr Neil McAuslane, Director

nmcauslane@cirsci.org

Dr Lawrence Liberti, Head, Regulatory Collaborations

lliberti@cirsci.org

Dr Magda Bujar, Manager, Strategic Development

mbujar@cirsci.org

Dr Tsz Hong Law, Scientific Analyst

tlaw@cirsci.org

Gill Hepton, Administrator

ghepton@cirsci.org

Prisha Patel, Manager, Global Development Programme

ppatel@cirsci.org

Dr Céline Rodier, Senior Research Analyst

crodier@cirsci.org

Dr Jenny Sharpe, Senior Scientific Writer

jsharpe@cirsci.org

Ting Wang, Manager, HTA Programme

twang@cirsci.org

Prof Stuart Walker, Founder

swalker@cirsci.org

Original artwork: Alan Chaston;
linesmandesign.co.uk

